Wolverine Trading, LLC Revance Therapeutics, Inc. Call Options Transaction History

Wolverine Trading, LLC

$97.8 Billion
Q1 2024

Call Options

24 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $143,220 - $286,748	30,800 Added 194.94%	46,600 $229,000
Q4 2023 Feb 14, 2024	SELL	$5.81 - $11.2 $7,552 - $14,559	-1,300 Reduced 7.6%	15,800 $138,000
Q3 2023 Nov 15, 2023	SELL	$11.47 - $25.07 $122,729 - $268,249	-10,700 Reduced 38.49%	17,100 $196,000
Q2 2023 Aug 23, 2023	SELL	$24.7 - $37.61 $1.07 Million - $1.63 Million	-43,400 Reduced 60.96%	27,800 $703,000
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $690,336 - $1.33 Million	37,600 Added 111.9%	71,200 $2.22 Million

Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $443,344 - $741,972	-24,200 Reduced 41.87%	33,600 $620,000
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $530,210 - $1.05 Million	37,000 Added 177.88%	57,800 $1.48 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $239,616 - $424,319	20,800 New	20,800 $296,000
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $241,020 - $396,045	-19,500 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $78,498 - $175,581	-6,300 Reduced 24.42%	19,500 $322,000
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $665,124 - $856,818	25,800 New	25,800 $715,000
Q2 2021 Aug 06, 2021	SELL	$26.8 - $31.84 $407,360 - $483,968	-15,200 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$24.03 - $29.97 $365,256 - $455,544	15,200 New	15,200 $423,000
Q4 2020 Feb 12, 2021	SELL	$23.41 - $28.34 $428,403 - $518,622	-18,300 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$23.23 - $34.3 $27,876 - $41,160	-1,200 Reduced 6.15%	18,300 $470,000
Q2 2020 Aug 13, 2020	BUY	$12.6 - $26.55 $119,700 - $252,225	9,500 Added 95.0%	19,500 $499,000
Q1 2020 May 11, 2020	SELL	$12.46 - $27.81 $73,514 - $164,079	-5,900 Reduced 37.11%	10,000 $154,000
Q4 2019 Feb 12, 2020	BUY	$11.66 - $20.15 $15,158 - $26,194	1,300 Added 8.9%	15,900 $256,000
Q3 2019 Nov 14, 2019	BUY	$10.22 - $14.5 $29,638 - $42,050	2,900 Added 24.79%	14,600 $201,000
Q1 2019 May 15, 2019	BUY	$15.4 - $20.39 $23,100 - $30,585	1,500 Added 14.71%	11,700 $184,000
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $54,179 - $74,880	-3,000 Reduced 22.73%	10,200 $198,000
Q3 2018 Nov 14, 2018	SELL	$23.55 - $30.1 $200,175 - $255,850	-8,500 Reduced 39.17%	13,200 $328,000
Q1 2018 May 15, 2018	SELL	$29.15 - $37.4 $314,820 - $403,920	-10,800 Reduced 33.23%	21,700 $668,000
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $797,875 - $1.18 Million	32,500	32,500 $1.16 Million

Others Institutions Holding RVNC

# of Institutions

214

Shares Held

83.4M

Call Options Held

656K

Put Options Held

424K

Capital World Investors Los Angeles, CA

13.9M
Shares

$35.8 Million
0.01% of portfolio
Black Rock Inc. New York, NY

7.31M
Shares

$18.8 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

6.28M
Shares

$16.1 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

5.4M
Shares

$13.9 Million
0.0% of portfolio
Palo Alto Investors LP Palo Alto, CA

5.25M
Shares

$13.5 Million
3.02% of portfolio

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account